Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal ant…
A tool used by the government for substance-use surveillance has consistently reported low rates of OUD. But the survey excluded a large group of Americans…
The conversation of VLR has sparked a discussion as to whether or not other COVID-19 treatment agents are associated with a surge in symptoms and…
This JAMA Insights illustrates how explanatory communication strategies can help improve patient comprehension, including adherence to treatment recommendations and self-management.
The decision is based on positive results from the CAHtalyst trials, which both met their primary and secondary end points.
This review focuses on DRESS, a serious drug-induced T-cell–mediated condition with marked cutaneous and systemic effects.
Objective The aim of this study was to explore parents’ views and experiences of managing preschool wheeze, including opinions on the use of investigations to…
Measuring end points such as molecular response, cytokines, and histomorphometry may show a greater range of benefits.
A December 2022 law introduced a new expedited withdrawal process for accelerated approvals. The first approval withdrawn with this pathway was that of melphalan flufenamide.
Audio Interview from the New England Journal of Medicine — Interview with Bindu Kanapuru on the FDA’s new expedited withdrawal procedure for accelerated approvals.
Drinking alcohol can cause all kinds of gastrointestinal upset, including diarrhea. A gastroenterology nurse practitioner shares how to prevent diarrhea from happening when alcohol is…
